{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:04:25Z","timestamp":1779293065787,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"DOI":"10.1186\/s12911-024-02794-8","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T11:45:02Z","timestamp":1734522302000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Continuous prediction for tumor mutation burden based on transcriptional data in gastrointestinal cancers"],"prefix":"10.1186","volume":"24","author":[{"given":"Beibei","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"3","key":"2794_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2794_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41571-021-00514-z","volume":"18","author":"I Soerjomataram","year":"2021","unstructured":"Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020\u20132070. Nat Rev Clin Oncol. 2021;18:663\u201372. https:\/\/doi.org\/10.1038\/s41571-021-00514-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2794_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21147\/j.issn.1000-9604.2021.01.02","volume":"33","author":"TC Zhang","year":"2021","unstructured":"Zhang TC, Chen H, Yin XL, He QF, Man JY, Yang XR, et al. Changing trends of disease burden of gastric cancer in China from 1990 to 2019 and its predictions: Findings from Global Burden of Disease Study. Chin J Cancer Res. 2021;33(1):11\u201326. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.01.02.","journal-title":"Chin J Cancer Res"},{"issue":"6","key":"2794_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00419-3","volume":"18","author":"AP Thrift","year":"2021","unstructured":"Thrift AP. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2021;18(6):432\u201343. https:\/\/doi.org\/10.1038\/s41575-021-00419-3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"2794_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.21147\/j.issn.1000-9604.2019.03.11","volume":"31","author":"J Yin","year":"2019","unstructured":"Yin J, Bai ZG, Zhang J, Zheng Z, Yao HG, Ye PP, et al. Burden of colorectal cancer in China, 1990\u20132017: Findings from the Global Burden of Disease Study 2017. Chin J Cancer Res. 2019;31(3):489\u201398. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2019.03.11.","journal-title":"Chin J Cancer Res"},{"issue":"26","key":"2794_CR6","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","journal-title":"N Engl J Med"},{"issue":"4","key":"2794_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, et al. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021;11(4):838\u201357. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1680.","journal-title":"Cancer Discov"},{"issue":"4","key":"2794_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/ol.2020.11905","volume":"20","author":"X Song","year":"2020","unstructured":"Song X, Qi W, Guo J, Sun L, Ding A, Zhao G, et al. Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress. Oncol Lett. 2020;20(4):46\u201353. https:\/\/doi.org\/10.3892\/ol.2020.11905.","journal-title":"Oncol Lett"},{"issue":"8","key":"2794_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","volume":"28","author":"N Riaz","year":"2016","unstructured":"Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 2016;28(8):411\u20139. https:\/\/doi.org\/10.1093\/intimm\/dxw019.","journal-title":"Int Immunol"},{"issue":"1","key":"2794_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13014-021-01853-y","volume":"16","author":"JD Stockton","year":"2021","unstructured":"Stockton JD, Tee L, Whalley C, James J, Dilworth M, Wheat R, et al. Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS\/AKT mutations and high tumour mutational burden. Radiation oncology (London, England). 2021;16(1):129. https:\/\/doi.org\/10.1186\/s13014-021-01853-y.","journal-title":"Radiation oncology (London, England)"},{"issue":"1","key":"2794_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12885-021-07942-1","volume":"21","author":"J Xiao","year":"2021","unstructured":"Xiao J, Li WY, Huang Y, Huang ML, Li SS, Zhai XH, et al. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer. 2021;21(1):282\u201393. https:\/\/doi.org\/10.1186\/s12885-021-07942-1.","journal-title":"BMC Cancer"},{"issue":"4","key":"2794_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.clcc.2019.08.001","volume":"18","author":"J Gong","year":"2019","unstructured":"Gong J, Robertson MD, Kim E, Fakih M, Schrock AB, Tam KW, et al. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden. Clin Colorectal Canc. 2019;18(4):307\u20139. https:\/\/doi.org\/10.1016\/j.clcc.2019.08.001.","journal-title":"Clin Colorectal Canc"},{"issue":"4","key":"2794_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10120-021-01175-8","volume":"24","author":"DQ Wang","year":"2021","unstructured":"Wang DQ, Wang N, Li XQ, Chen XF, Shen B, Zhu DQ, et al. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia. Gastric Cancer. 2021;24(4):823\u201334. https:\/\/doi.org\/10.1007\/s10120-021-01175-8.","journal-title":"Gastric Cancer"},{"issue":"9","key":"2794_CR14","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","volume":"30","author":"F Wang","year":"2019","unstructured":"Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479\u201386. https:\/\/doi.org\/10.1093\/annonc\/mdz197.","journal-title":"Ann Oncol"},{"issue":"6","key":"2794_CR15","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1007\/s10120-021-01207-3","volume":"24","author":"Z Li","year":"2021","unstructured":"Li Z, Jia Y, Zhu H, Xing X, Pang F, Shan F, et al. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric cancer\u202f: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2021;24(6):1342\u201354. https:\/\/doi.org\/10.1007\/s10120-021-01207-3.","journal-title":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"issue":"5","key":"2794_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/jamaoncol.2018.7098","volume":"5","author":"ZJ Wang","year":"2019","unstructured":"Wang ZJ, Duan JC, Cai SL, Han M, Dong H, Zhao J, et al. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncol. 2019;5(5):696\u2013702. https:\/\/doi.org\/10.1001\/jamaoncol.2018.7098.","journal-title":"JAMA Oncol"},{"key":"2794_CR17","doi-asserted-by":"publisher","first-page":"618313","DOI":"10.3389\/fcell.2021.618313","volume":"9","author":"DD Yang","year":"2021","unstructured":"Yang DD, Yu JL, Han B, Sun Y, Mo S, Hu J. Long Non-coding RNA Expression Patterns in Stomach Adenocarcinoma Serve as an Indicator of Tumor Mutation Burden and Are Associated With Tumor-Infiltrating Lymphocytes and Microsatellite Instability. Front Cell Dev Biol. 2021;9:618313. https:\/\/doi.org\/10.3389\/fcell.2021.618313.","journal-title":"Front Cell Dev Biol"},{"key":"2794_CR18","doi-asserted-by":"publisher","first-page":"1686480","DOI":"10.1155\/2020\/1686480","volume":"2020","author":"Y Xia","year":"2020","unstructured":"Xia Y, Wang Q, Huang XL, Yin XH, Song JK, Ke Z, et al. miRNA-Based Feature Classifier Is Associated with Tumor Mutational Burden in Head and Neck Squamous Cell Carcinoma. Biomed Res Int. 2020;2020:1686480. https:\/\/doi.org\/10.1155\/2020\/1686480.","journal-title":"Biomed Res Int"},{"issue":"15_suppl","key":"2794_CR19","doi-asserted-by":"publisher","first-page":"e15244","DOI":"10.1200\/JCO.2020.38.15_suppl.e15244","volume":"8","author":"RP Joshi","year":"2020","unstructured":"Joshi RP, Kruger AJ, Sha L, Kannan M, Khan AA, Stumpe M. Learning relevant H&E slide morphologies for prediction of colorectal cancer tumor mutation burden using weakly supervised deep learning. Journal of Clinical Oncology. 2020;8(15_suppl):e15244\u2013e15244. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.e15244.","journal-title":"Journal of Clinical Oncology."},{"issue":"3","key":"2794_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","volume":"18","author":"H Akoglu","year":"2018","unstructured":"Akoglu H. User\u2019s guide to correlation coefficients. Turkish Journal of Emergency Medicine. 2018;18(3):91\u20133. https:\/\/doi.org\/10.1016\/j.tjem.2018.08.001.","journal-title":"Turkish Journal of Emergency Medicine"},{"key":"2794_CR21","doi-asserted-by":"publisher","first-page":"623424","DOI":"10.3389\/fgene.2021.623424","volume":"12","author":"ZJ Zhou","year":"2021","unstructured":"Zhou ZJ, Xie X, Wang X, Zhang X, Li WX, Sun TH, et al. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer. Front Genet. 2021;12:623424. https:\/\/doi.org\/10.3389\/fgene.2021.623424.","journal-title":"Front Genet"},{"issue":"1","key":"2794_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4251\/wjgo.v13.i1.37","volume":"13","author":"DY Zhao","year":"2021","unstructured":"Zhao DY, Sun XZ, Yao SK. Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer. World J Gastro Oncol. 2021;13(1):37\u201357. https:\/\/doi.org\/10.4251\/wjgo.v13.i1.37.","journal-title":"World J Gastro Oncol"},{"issue":"5","key":"2794_CR23","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.18632\/aging.102917","volume":"12","author":"C Yuan","year":"2020","unstructured":"Yuan C, Xiang LY, Cao K, Zhang JG, Luo Y, Sun WJ, et al. The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy. Aging (Albany NY). 2020;12(5):4603\u201316. https:\/\/doi.org\/10.18632\/aging.102917.","journal-title":"Aging (Albany NY)"},{"key":"2794_CR24","doi-asserted-by":"publisher","first-page":"626912","DOI":"10.3389\/fonc.2020.626912","volume":"10","author":"ZK Ning","year":"2020","unstructured":"Ning ZK, Hu CG, Huang C, Liu J, Zhou TC, Zong Z. Molecular Subtypes and CD4(+) Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer. Front Oncol. 2020;10:626912. https:\/\/doi.org\/10.3389\/fonc.2020.626912.","journal-title":"Front Oncol"},{"key":"2794_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2016.10.014","volume":"41","author":"QY Ma","year":"2016","unstructured":"Ma QY, Huang DY, Zhang HJ, Chen J, Miller W, Chen XF. Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer. Int Immunopharmacol. 2016;41:1\u20137. https:\/\/doi.org\/10.1016\/j.intimp.2016.10.014.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"2794_CR26","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1172\/Jci67428","volume":"123","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873\u201392. https:\/\/doi.org\/10.1172\/Jci67428.","journal-title":"J Clin Invest"},{"key":"2794_CR27","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.2147\/OTT.S101884","volume":"9","author":"K Li","year":"2016","unstructured":"Li K, Chen FC, Xie HJ. Decreased FOXP3+ and GARP+ Tregs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer. Onco Targets Ther. 2016;9:3525\u201333. https:\/\/doi.org\/10.2147\/OTT.S101884.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"2794_CR28","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.21873\/anticanres.14917","volume":"41","author":"Y Nakanishi","year":"2021","unstructured":"Nakanishi Y, Hirota S, Hojo Y, Nakamura T, Kumamoto T, Kurahashi Y, et al. Pathological Complete Remission of Liver Metastases Correlates With Elimination of Tumor-infiltrating Tregs in Gastric Cancer. Anticancer Res. 2021;41(3):1571\u20137. https:\/\/doi.org\/10.21873\/anticanres.14917.","journal-title":"Anticancer Res"},{"issue":"2","key":"2794_CR29","doi-asserted-by":"publisher","first-page":"e000826","DOI":"10.1136\/jitc-2020-000826","volume":"8","author":"DB Ji","year":"2020","unstructured":"Ji DB, Song C, Li YH, Xia JH, Wu YJ, Jia JY, et al. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer. J Immunother Cancer. 2020;8(2):e000826. https:\/\/doi.org\/10.1136\/jitc-2020-000826.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2794_CR30","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/2326-6066.Cir-17-0698","volume":"6","author":"A Rizzo","year":"2018","unstructured":"Rizzo A, Di Giovangiulio M, Stolfi C, Franz\u00e8 E, Fehling HJ, Carsetti R, et al. ROR\u03b3t-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells. Cancer Immunol Res. 2018;6(9):1082\u201392. https:\/\/doi.org\/10.1158\/2326-6066.Cir-17-0698.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2794_CR31","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1021\/acsnano.8b02446","volume":"12","author":"YW Choo","year":"2018","unstructured":"Choo YW, Kang M, Kim HY, Han J, Kang S, Lee JR, et al. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. ACS Nano. 2018;12(9):8977\u201393. https:\/\/doi.org\/10.1021\/acsnano.8b02446.","journal-title":"ACS Nano"},{"issue":"4","key":"2794_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/carcin\/bgaa128","volume":"42","author":"CH Jiang","year":"2021","unstructured":"Jiang CH, Liang WH, Li FP, Xie YF, Yuan X, Zhang HJ, et al. Distribution and prognostic impact of M1 macrophage on esophageal squamous cell carcinoma. Carcinogenesis. 2021;42(4):537\u201345. https:\/\/doi.org\/10.1093\/carcin\/bgaa128.","journal-title":"Carcinogenesis"},{"issue":"20","key":"2794_CR33","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1158\/1078-0432.Ccr-19-1105","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Han SW, Bae JM, Jang H, Han H, Kim H, et al. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2019;25(20):6141\u20137. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1105.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"2794_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/cancers13010141","volume":"13","author":"J Huang","year":"2021","unstructured":"Huang J, Koulaouzidis A, Marlicz W, Lok V, Chu C, Ngai CH, et al. Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries. Cancers (Basel). 2021;13(1):141. https:\/\/doi.org\/10.3390\/cancers13010141.","journal-title":"Cancers (Basel)."},{"key":"2794_CR35","doi-asserted-by":"publisher","first-page":"792340","DOI":"10.3389\/fonc.2021.792340","volume":"11","author":"HR Kim","year":"2021","unstructured":"Kim HR, Ahn S, Jo H, Kim H, Hong J, Lee J, et al. The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. Front Oncol. 2021;11:792340. https:\/\/doi.org\/10.3389\/fonc.2021.792340.","journal-title":"Front Oncol"},{"issue":"1","key":"2794_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/cancers15010269","volume":"15","author":"YY Hsieh","year":"2022","unstructured":"Hsieh YY, Kuo WL, Hsu WT, Tung SY, Li C. Fusobacterium Nucleatum-Induced Tumor Mutation Burden Predicts Poor Survival of Gastric Cancer Patients. Cancers. 2022;15(1):269. https:\/\/doi.org\/10.3390\/cancers15010269.","journal-title":"Cancers."}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-024-02794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-024-02794-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-024-02794-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T12:04:02Z","timestamp":1734523442000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-024-02794-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2794"],"URL":"https:\/\/doi.org\/10.1186\/s12911-024-02794-8","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"19 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Transcriptional, clinical and somatic mutational data are downloaded from public database, and there is no privacy leakage here.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Clinical characteristics are obtained from TCGA, and no consent for publication is needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}